CPRX — Catalyst Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $2.75bn
- $2.23bn
- $491.73m
- 93
- 53
- 92
- 94
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 15.01 | ||
| PEG Ratio (f) | 1.46 | ||
| EPS Growth (f) | 11.5% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.77 | ||
| Price to Tang. Book | 4.81 | ||
| Price to Free Cashflow | 11.48 | ||
| Price to Sales | 5.59 | ||
| EV to EBITDA | 9.57 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 26.7% | ||
| Return on Equity | 29.38% | ||
| Operating Margin | 39.68% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 119.07 | 140.83 | 214.2 | 398.2 | 491.73 | 556.5 | 605.94 | 36.89% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +134.75 | -48.1 | +103.66 | -15.84 | +108.95 | +8.64 | +17.68 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Directors
- Patrick McEnany CHM (73)
- Alicia Grande CFO (50)
- Steven Miller COO (59)
- Brian Elsbernd CCO (57)
- Mary Coleman VPR
- Jeffrey Del Carmen OTH (50)
- Gary Ingenito OTH (65)
- Charles O'Keeffe LED (81)
- Molly Harper DRC
- Philip Coelho IND (77)
- Richard Daly IND (68)
- Donald Denkhaus IND (74)
- David Tierney IND (57)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 21st, 2006
- Public Since
- November 8th, 2006
- No. of Shareholders
- 17
- No. of Employees
- 181
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 121,959,172
- Address
- 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES, 33134
- Web
- https://catalystpharma.com/
- Phone
- +1 3055292522
- Auditors
- Grant Thornton LLP
Upcoming Events for CPRX
Catalyst Pharmaceuticals Inc Annual Shareholders Meeting
Catalyst Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Catalyst Pharmaceuticals Inc Earnings Release
Similar to CPRX
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
ASP Isotopes
NASDAQ Capital Market
FAQ
What is the Catalyst Pharmaceuticals share price?
As of Today at 19:49 UTC, shares in Catalyst Pharmaceuticals are trading at $22.52. This share price information is delayed by 15 minutes.
How has the Catalyst Pharmaceuticals share price performed this year?
Shares in Catalyst Pharmaceuticals last closed at $22.52 and the price had moved by +40.75% over the past 365 days. In terms of relative price strength the Catalyst Pharmaceuticals share price has outperformed the S&P500 Index by +32.34% over the past year.
What are the analyst and broker recommendations for Catalyst Pharmaceuticals?
The overall consensus recommendation for Catalyst Pharmaceuticals is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Catalyst Pharmaceuticals dividend yield?
Catalyst Pharmaceuticals does not currently pay a dividend.
Does Catalyst Pharmaceuticals pay a dividend?
Catalyst Pharmaceuticals does not currently pay a dividend.
When does Catalyst Pharmaceuticals next pay dividends?
Catalyst Pharmaceuticals does not currently pay a dividend.
How do I buy Catalyst Pharmaceuticals shares?
To buy shares in Catalyst Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Catalyst Pharmaceuticals?
As of the previous close price of $22.52, shares in Catalyst Pharmaceuticals had a market capitalisation of $2.75bn.
Where are Catalyst Pharmaceuticals shares listed?
Here are the trading details for Catalyst Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CPRX
What kind of share is Catalyst Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Catalyst Pharmaceuticals is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Catalyst Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Catalyst Pharmaceuticals is $33.88. That is 50.44% above the last closing price of $22.52.
Analysts covering Catalyst Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of $1.43 for the next financial year.
Find out moreWhat is the trend in the Catalyst Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Catalyst Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +17.49%.
As of the last closing price of $22.52, shares in Catalyst Pharmaceuticals were trading +7.43% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Catalyst Pharmaceuticals PE Ratio?
The Catalyst Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 15.01. The shares last closed at $22.52.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals' management team is headed by:
- Patrick McEnany - CHM
- Alicia Grande - CFO
- Steven Miller - COO
- Brian Elsbernd - CCO
- Mary Coleman - VPR
- Jeffrey Del Carmen - OTH
- Gary Ingenito - OTH
- Charles O'Keeffe - LED
- Molly Harper - DRC
- Philip Coelho - IND
- Richard Daly - IND
- Donald Denkhaus - IND
- David Tierney - IND